Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Among the posters, Alkermes presented results from a real-world, retrospective study of healthcare resource utilization (HCRU) and treatment patterns in patients with schizophrenia and patients with ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

State of Alaska Department of Revenue decreased its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 5.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned ...

Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...